DACI 500 mg Vial - A Potent Antineoplastic Agent

DACI 500 mg Vial contains Dactinomycin, also known as Actinomycin D, a powerful antineoplastic agent vital in chemotherapy regimens.
This medication is specifically formulated to inhibit the growth and spread of cancer cells.
It is a prescription-only drug, strictly administered intravenously by qualified healthcare professionals.
The use of DACI 500 mg Vial is a crucial component in the treatment of various malignant conditions, requiring careful medical supervision and expertise.

Product Details

• Form: Powder for solution for injection
• Concentration: 500 mg
• Administration Route: Intravenous
• Drug Type: Prescription drug (antineoplastic)
• Package Type: Vial
• Active Principle: Dactinomycin

Ingredients

DACI 500 mg Vial primarily contains:

• Active Ingredient: Dactinomycin 500 mg

Benefits of Use

DACI 500 mg Vial offers significant therapeutic benefits in oncology:

• Potent Antineoplastic Action: Effectively targets and inhibits the growth of rapidly dividing cancer cells by interfering with DNA and RNA synthesis.
• Broad-Spectrum Efficacy: Used in the treatment of various cancer types, including Wilms' tumor, rhabdomyosarcoma, Ewing's sarcoma, non-seminomatous testicular cancer, and gestational trophoblastic tumors.
• Established Treatment Protocol: A fundamental drug in specific chemotherapy protocols, contributing to improved patient outcomes when appropriately administered.

How to Use

DACI 500 mg Vial must only be administered by a healthcare professional experienced in the use of antineoplastic agents.

1. Reconstitution: The contents of the vial are typically reconstituted with sterile water for injection, following specific guidelines.
2. Dilution: The reconstituted solution is then further diluted using appropriate intravenous fluids (e.g., Dextrose 5% or Sodium Chloride 0.9%) to achieve the desired concentration.
3. Administration: Administered intravenously over a specified period, typically as a slow infusion.
4. Dosage: The dose and administration schedule are highly individualized based on the patient's condition, type of cancer, body surface area, and response to treatment.
5. Monitoring: Close monitoring for side effects and efficacy is essential throughout the treatment period.

Caution & Warnings

Due to its potent nature and potential for serious side effects, DACI 500 mg Vial requires strict adherence to medical protocols:

• Medical Supervision: Administration must be under the direct supervision of a physician experienced in cancer chemotherapy.
• Bone Marrow Suppression: Can cause severe bone marrow suppression, leading to anemia, leukopenia, and thrombocytopenia. Regular blood counts are mandatory.
• Hepatotoxicity and Nephrotoxicity: Potential for liver and kidney damage; liver and kidney function must be monitored.
• Extravasation Risk: Highly vesicant; extravasation during intravenous administration can cause severe local tissue damage and necrosis.
• Gastrointestinal Effects: Common side effects include nausea, vomiting, stomatitis, and diarrhea.
• Pregnancy and Lactation: Contraindicated during pregnancy and lactation due to its teratogenic and mutagenic properties. Effective contraception is required for patients of reproductive potential.
• Drug Interactions: Caution is advised when co-administering with other myelosuppressive agents or radiation therapy.
• Handling Precautions: Must be handled with care by trained personnel using appropriate protective equipment, following guidelines for cytotoxic agents.
• Storage: Store according to the manufacturer's instructions.